SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-125926
Filing Date
2024-11-13
Accepted
2024-11-13 07:04:15
Documents
13
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mura-20241113.htm   iXBRL 8-K 50186
2 EX-99.1 mura-ex99_1.htm EX-99.1 97963
3 GRAPHIC img134125358_0.jpg GRAPHIC 100951
  Complete submission text file 0000950170-24-125926.txt   417109

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mura-20241113.xsd EX-101.SCH 28024
15 EXTRACTED XBRL INSTANCE DOCUMENT mura-20241113_htm.xml XML 4682
Mailing Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380
Business Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 353 1 905 8020
Mural Oncology plc (Filer) CIK: 0001971543 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41837 | Film No.: 241451135
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)